The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Emerging role of natural products in cancer immunotherapy
Open accessAbstract
Cancer immunotherapy has become a new generation of anti-tumor treatment, but its indications still focus on several types of tumors that are sensitive to the immune system. Therefore, effective strategies that can expand its indications and enhance its efficiency become the key element for the further development of cancer immunotherapy. Natural products are reported to have this effect on cancer immunotherapy, including cancer vaccines, immune-check points inhibitors, and adoptive immune-cells therapy. And the mechanism of that is mainly attributed to the remodeling of the tumor-immunosuppressive microenvironment, which is the key factor that assists tumor to avoid the recognition and attack from immune system and cancer immunotherapy. Therefore, this review summarizes and concludes the natural products that reportedly improve cancer immunotherapy and investigates the mechanism. And we found that saponins, polysaccharides, and flavonoids are mainly three categories of natural products, which reflected significant effects combined with cancer immunotherapy through reversing the tumor-immunosuppressive microenvironment. Besides, this review also collected the studies about nano-technology used to improve the disadvantages of natural products. All of these studies showed the great potential of natural products in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, S., Zhou, L., Zhang, M., Wang, Y., Wang, M., Du, J., Gu, W., Kui, F., Li, J., Geng, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01658 · Cited by 37
Self-citationRetractedDendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
The effects of β-glucan on human immune and cancer cells
Chan, G. C.-F., Chan, W. K., & Sze, D. M.-Y. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-25 · Cited by 862
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Kirkwood, J. M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M. S., & Rao, U. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1103-3 · Cited by 552
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Advances in saponin-based adjuvants
Sun, H.-X., Xie, Y., & Ye, Y.-P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.091 · Cited by 471
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression
Kim, R., Emi, M., Tanabe, K., & Arihiro, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4128 · Cited by 445
Wu, L., D’Amico, A., Winkel, K. D., Suter, M., Lo, D., & Shortman, K. (1998) · Immunity · doi:10.1016/s1074-7613(00)80649-4 · Cited by 438
Differential release of mast cell mediators and the pathogenesis of inflammation
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00519.x · Cited by 425
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
O'Leary, M. C., Lu, X., Huang, Y., Lin, X., Mahmood, I., Przepiorka, D., Gavin, D., Lee, S., Liu, K., George, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2035 · Cited by 298
Hu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01522 · Cited by 292
Ito, K., Nakazato, T., Yamato, K., Miyakawa, Y., Yamada, T., Hozumi, N., Segawa, K., Ikeda, Y., & Kizaki, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1670 · Cited by 287
Antitumor effects of immunity-enhancing traditional Chinese medicine
Wang, Y., Zhang, Q., Chen, Y., Liang, C.-L., Liu, H., Qiu, F., & Dai, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109570 · Cited by 287
Self-citationButterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 256
The dawn of vaccines for cancer prevention
Finn, O. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.140 · Cited by 254
Intracellular mechanisms of antigen cross presentation in dendritic cells
Amigorena, S., & Savina, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.022 · Cited by 247
Ward, A. B., Mir, H., Kapur, N., Gales, D. N., Carriere, P. P., & Singh, S. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1400-z · Cited by 245
Polysaccharides as vaccine adjuvants
Sun, B., Yu, S., Zhao, D., Guo, S., Wang, X., & Zhao, K. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.040 · Cited by 238
IL-10, an inflammatory/inhibitory cytokine, but not always
Conti, P., Kempuraj, D., Kandere, K., Gioacchino, M. D., Barbacane, R. C., Castellani, M. L., Felaco, M., Boucher, W., Letourneau, R., & Theoharides, T. C. (2003) · Immunology Letters · doi:10.1016/s0165-2478(03)00002-6 · Cited by 235
Gutzmer, R., Diestel, C., Mommert, S., Köther, B., Stark, H., Wittmann, M., & Werfel, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5224 · Cited by 232
Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma
Takanami, I., Takeuchi, K., & Naruke, M. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2686::aid-cncr6>3.0.co;2-6 · Cited by 231
Prestipino, A., Emhardt, A. J., Aumann, K., O’Sullivan, D., Gorantla, S. P., Duquesne, S., Melchinger, W., Braun, L., Vuckovic, S., Boerries, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7729 · Cited by 229
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Bouchkouj, N., Kasamon, Y. L., de Claro, R. A., George, B., Lin, X., Lee, S., Blumenthal, G. M., Bryan, W., McKee, A. E., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2743 · Cited by 226
Dendrimers in combination with natural products and analogues as anti-cancer agents
Mignani, S., Rodrigues, J., Tomas, H., Zablocka, M., Shi, X., Caminade, A.-M., & Majoral, J.-P. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00550d · Cited by 219
Livingston, P. O., Adluri, S., Helling, F., Yao, T.-J., Kensilt, C. R., Newman, M. J., & Marciani, D. (1994) · Vaccine · doi:10.1016/s0264-410x(94)80052-2 · Cited by 214
Gilewski, T. A., Adluri, S., Ragupathi, G., Zhang, S., Yao, T., Panageas, K., Moynahan, M. E., Houghton, A., Norton, L., & Livingston, P. O. (2000) · PubMed · Cited by 203
Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity
Marciani, D. J., Press, J. B., Reynolds, R. C., Pathak, A. K., Pathak, V., Gundy, L. E., Farmer, J. T., Koratich, M. S., & May, R. D. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00118-3 · Cited by 196
Xu, L., Zhang, Y., Tian, K., Chen, X., Zhang, R., Mu, X., Wu, Y., Wang, D., Wang, S., Liu, F., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0929-6 · Cited by 177
Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation
COLEMAN, J. W. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2002.01918.x · Cited by 173
Fontana, F., Raimondi, M., Marzagalli, M., Domizio, A. D., & Limonta, P. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188338 · Cited by 173
Xu, H., Hu, M., Liu, M., An, S., Guan, K., Wang, M., Li, L., Zhang, J., Li, J., & Huang, L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119769 · Cited by 173
Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells
Basu, S., & Srivastava, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407780102 · Cited by 167
Jung, M.-Y., Kang, H.-J., & Moon, A. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00426-8 · Cited by 163
Xiao, Z., Su, Z., Han, S., Huang, J., Lin, L., & Shuai, X. (2020) · Science Advances · doi:10.1126/sciadv.aay7785 · Cited by 161
Zhang, J., Shen, L., Li, X., Song, W., Liu, Y., & Huang, L. (2019) · ACS Nano · doi:10.1021/acsnano.9b02875 · Cited by 159
Sotomayor, E. M., Borrello, I., Tubb, E. E., Allison, J. P., & Levitsky, H. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11476 · Cited by 157
O’Sullivan, B., & Thomas, R. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5491 · Cited by 155
Sabbatini, P. J., Ragupathi, G., Hood, C., Aghajanian, C. A., Juretzka, M. M., Iasonos, A. E., Hensley, M. L., Spassova, M. K., Ouerfelli, O., Spriggs, D. R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2949 · Cited by 155
Liang, J., Li, H., Chen, J., He, L., Du, X., Zhou, L., Xiong, Q., Lai, X., Yang, Y., Huang, S. M., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104417 · Cited by 153
Bioactive compounds and health benefits of edible Rumex species-A review
Mishra, A. P., Sharifi‐Rad, M., Shariati, M. A., Mabkhot, Y. N., Al–Showiman, S. S., Rauf, A., Salehi, B., Župunski, M., Sharifi‐Rad, M., Gusain, P., et al. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2018.64.8.5 · Cited by 152
Ke, M., Zhang, Z., Xu, B.-Y., Zhao, S., Ding, Y., Wu, X., Wu, R., Lv, Y., & Dong, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105824 · Cited by 151
Jiang, Z., Yang, Y., Yang, Y., Zhang, Y., Yue, Z., Pan, Z., & Ren, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.129 · Cited by 144
Huang, Y., Chen, Y., Zhou, S., Liang, C., Wang, J., Pei, Y., Xu, M., Feng, J., Jiang, T., Liang, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14425-7 · Cited by 144
Butterfield, L. H., & 易宗毕 (2015) · doi:10.3760/cma.j.issn.1007-9742.2015.11.117 · Cited by 144
Cancer immunotherapy comes of age and looks for maturity
Finck, A., Gill, S. I., & June, C. H. (2020) · Nature Communications · doi:10.1038/s41467-020-17140-5 · Cited by 143
Chen, H., Wang, P.-H., Chen, S.-S., Wen, C.-C., Chen, Y., Yang, W., & Yang, N. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1258-9 · Cited by 141
Collateral sensitivity of natural products in drug-resistant cancer cells
Efferth, T., Saeed, M. E. M., Kadioglu, O., Seo, E., Shirooie, S., Mbaveng, A. T., Nabavi, S. M., & Kuete, V. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.01.009 · Cited by 140
Ragupathi, G., Meyers, M. L., Adluri, S., Howard, L., Musselli, C., & Livingston, P. O. (2000) · International Journal of Cancer · Cited by 131
Coombs, M. R. P., Harrison, M. E., & Hoskin, D. W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.023 · Cited by 126
Krug, L. M., Ragupathi, G., Hood, C., Kris, M. G., Miller, V. A., Allen, J. R., Keding, S. J., Danishefsky, S. J., Gomez, J. E., Tyson, L. B., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0482 · Cited by 125
Jeong, Y.-I., Kim, S. W., Jung, I. D., Lee, J. S., Chang, J. H., Lee, C.-M., Chun, S. H., Yoon, M., Kim, G. T., Ryu, S. W., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807328200 · Cited by 123
The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer
Khazaie, K., & von Boehmer, H. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.006 · Cited by 122
Dong, M., Meng, Z., Kuerban, K., Qi, F., Liu, J., Wei, Y., Wang, Q., Jiang, S., Feng, M., & Ye, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1099-3 · Cited by 119
Slovin, S. F., Ragupathi, G., Musselli, C., Fernandez, C., Diani, M., Verbel, D., Danishefsky, S. J., Livingston, P. O., & Scher, H. I. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0598-5 · Cited by 116
Wang, Z., Li, M. Y., Zhang, Z. H., Zuo, H. X., Wang, J. Y., Xing, Y., Ri, M., Jin, H. L., Jin, C. H., Xu, G. H., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104727 · Cited by 115
Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control
Sudhakaran, M., Sardesai, S. D., & Doseff, A. I. (2019) · Antioxidants · doi:10.3390/antiox8040103 · Cited by 114
Huang, T., CHEN, Z., & FANG, L. (2012) · Oncology Reports · doi:10.3892/or.2012.2080 · Cited by 113
Talimogene Laherparepvec for the Treatment of Advanced Melanoma
Ott, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2709 · Cited by 111
Lu, Y., Miao, L., Wang, Y., Xu, Z., Zhao, Y. D., Shen, Y., Xiang, G., & Huang, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.165 · Cited by 109
Self-citationRegulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed · Cited by 109
Fernández‐Tejada, A., Tan, D. S., & Gin, D. Y. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00242 · Cited by 108
Lin, T.-J., Lin, H.-T., Chang, W.-T., Pradeep Mitapalli., S., Hsiao, P., Yin, S., & Yang, N. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0435-9 · Cited by 105
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 105
Non-apoptotic cell death in malignant tumor cells and natural compounds
Ye, J., Zhang, R., Wu, F., Zhai, L., Wang, K., Xiao, M., Xie, T., & Sui, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.061 · Cited by 105
Ragupathi, G., Livingston, P. O., Hood, C., Gathuru, J., Krown, S. E., Chapman, P. B., Wolchok, J. D., Williams, L. J., Oldfield, R. C., & Hwu, W. (2003) · PubMed · Cited by 103
Nutrigenomics in cancer: Revisiting the effects of natural compounds
Braicu, C., Mehterov, N. H., Vladimirov, B., Sarafian, V. S., Nabavi, S. M., Atanasov, A. G., & Berindan‐Neagoe, I. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.011 · Cited by 102
Kamat, A. M., Tharakan, S. T., Sung, B., & Aggarwal, B. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2045 · Cited by 101
Lee, S. H., Krisanapun, C., & Baek, S. J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq016 · Cited by 98
Oxidative stress stimulates IL‐4 and IL‐6 production in mast cells by an APE/Ref‐1‐dependent pathway
Frossi, B., Carli, M., Daniel, K. C., Rivera, J., & Pucillo, C. E. M. (2003) · European Journal of Immunology · doi:10.1002/eji.200323995 · Cited by 95
Pei, Y., Liang, C., Huang, Y., Wang, J., Feng, J., Xu, M., Chen, Y., Song, Q., Jiang, G., Gu, X. Q., et al. (2019) · Small · doi:10.1002/smll.201900631 · Cited by 93
Yu, H., Yang, Y., Jiang, T., Zhang, X., Zhao, Y., Pang, G., Feng, Y., Zhang, S., Wang, F., Wang, Y., et al. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b07804 · Cited by 88
Self-citationKongtawelert, P., Wudtiwai, B., Shwe, T. H., Pothacharoen, P., & Phitak, T. (2020) · Molecules · doi:10.3390/molecules25020252 · Cited by 86
The Potential Antitumor Effects of Capsaicin
Díaz‐Laviada, I., & Rodríguez‐Henche, N. (2014) · Springer eBooks · doi:10.1007/978-3-0348-0828-6_8 · Cited by 85
Design and Synthesis of Potent Quillaja Saponin Vaccine Adjuvants
Adams, M. M., Damani, P., Perl, N. R., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja9082842 · Cited by 85
Mazewski, C., Kim, M. S., & de Mejı́a, E. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-47903-0 · Cited by 84
Mast cells as regulators of adaptive immunity to tumours
Wasiuk, A., de Vries, V. C., Hartmann, K., Roers, A., & Noelle, R. J. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03840.x · Cited by 82
SA-49, a Novel Aloperine Derivative, Induces MITF-Dependent Lysosomal Degradation of PD-L1
Zhang, N., Dou, Y., Liu, L., Zhang, X., Liu, X., Zeng, Q., Liu, Y., Yin, M., Liu, X., Deng, H., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.054 · Cited by 80
Mokbel, K., Wazir, U., & Mokbel, K. (2019) · Anticancer Research · doi:10.21873/anticanres.13720 · Cited by 80
Hu, M., Yang, J. F., Qu, L., Deng, X., Duan, Z., Fu, R., Liang, L., & Fan, D. (2019) · Food & Function · doi:10.1039/c9fo02166c · Cited by 77
A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”
Slovin, S. F., Ragupathi, G., Fernandez, C., Diani, M., Jefferson, M. P., Wilton, A. S., Kelly, W. K., Morris, M. J., Solit, D. B., Clausen, H., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0335-y · Cited by 76
Gu, P., Liu, Z., Sun, Y., Ou, N., Hu, Y., Liu, J., Wu, Y., & Wang, D. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.11.008 · Cited by 76
Bi, S., Huang, W., Chen, S., Huang, C., Li, C., Guo, Z., Yang, J., Zhu, J., Song, L., & Yu, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.050 · Cited by 76
Natural products as mediators of disease
Garg, N., Luzzatto‐Knaan, T., Melnik, A. V., Caraballo‐Rodríguez, A. M., Floros, D. J., Petras, D., Gregor, R., Dorrestein, P. C., & Phelan, V. V. (2016) · Natural Product Reports · doi:10.1039/c6np00063k · Cited by 74
Histamine and migraine revisited: mechanisms and possible drug targets
Worm, J., Falkenberg, K., & Olesen, J. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-0984-1 · Cited by 71
Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells
Zhang, Y., Yang, S., Yang, Y., & Liu, T. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0247-4 · Cited by 69
Son, K.-J., Choi, K. R., Lee, S. J., & Lee, H. (2016) · Immune Network · doi:10.4110/in.2016.16.1.75 · Cited by 67
Fitzpatrick, J.-M., Minogue, E., Curham, L. M., Tyrrell, H., Gavigan, P., Hind, W. H., & Downer, E. J. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577217 · Cited by 67
Cuyàs, E., Pérez-Sánchez, A., Micol, V., Menéndez, J. A., & Bosch‐Barrera, J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1245249 · Cited by 65
Han, Z., Liu, S., Lin, H., Trivett, A. L., Hannifin, S., Yang, D., & Oppenheim, J. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02338-4 · Cited by 65
Immunomodulation of Curcumin on Adoptive Therapy with T Cell Functional Imaging in Mice
Chang, Y.-F., Chuang, H., Hsu, C.-H., Liu, R.-S., Gambhir, S. S., & Hwang, J. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0308 · Cited by 64
Xu, R., Wu, J., Zhang, X., Zou, X., Li, C., Wang, H., Yuan, M., Chen, M., Sun, Q., & Liu, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104623 · Cited by 64
Chang, W. T., Lai, T.-H., Chyan, Y., Yin, S. Y., Chen, Y., Wei, W. C., & Yang, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122374 · Cited by 63
Modulation of regulatory T cells by natural products in cancer
Bahrami, A., Fereidouni, M., Pirro, M., Bianconi, V., & Sahebkar, A. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.001 · Cited by 62
Teoh, C., & Davies, K. J. A. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.12.001 · Cited by 56
FDA approves new upgraded Gardasil 9
Kirby, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71191-x · Cited by 54
Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications
Chhabra, G., Singh, C. K., Ndiaye, M. A., Fedorowicz, S., Molot, A., & Ahmad, N. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.025 · Cited by 54
Liu, S., Han, Z., Trivett, A. L., Lin, H., Hannifin, S., Yang, D., & Oppenheim, J. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02326-8 · Cited by 52
Natural modulators of the hallmarks of immunogenic cell death
Radogna, F., Dicato, M. A., & Diederich, M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.016 · Cited by 50
Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release
Liu, W., Fan, T., Li, M., Zhang, G., Guo, W., Yang, X., Jiang, C., Li, X., Xu, X., Anshu, T., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106206 · Cited by 49
Ju, S., Park, S., Lee, Y., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26316 · Cited by 48
Granato, M., Montani, M. S. G., Filardi, M. R., Faggioni, A., & Cirone, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4911 · Cited by 43
Branca, M. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3690 · Cited by 43
Fontana, F., Raimondi, M., Domizio, A. D., Moretti, R. M., Marelli, M. M., & Limonta, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.011 · Cited by 43
Banerjee, S., Ghosh, T., Barik, S., Das, A., Ghosh, S., Bhuniya, A., Bose, A., & Baral, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110040 · Cited by 42
Lin, C., Pan, I.-H., Li, Y., Pan, Y., Lin, M., Lu, Y., Wu, H.-C., & Chu, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116191 · Cited by 42
He, J., Yin, P., & Xu, K. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s223646 · Cited by 42
Hsu, P., Lin, Y.-H., Yeh, E.-L., Lo, H., Hsu, T., & Su, C.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.21477 · Cited by 39
New perspectives for natural triterpene glycosides as potential adjuvants
Lacaille‐Dubois, M., & Wagner, H. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.10.019 · Cited by 39
Alatrash, G., Qiao, N., Zhang, M., Zope, M., Perakis, A. A., Sukhumalchandra, P., Philips, A. V., Garber, H. R., Kerros, C., John, L. S. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1527 · Cited by 39
Pi, C.-C., Chu, C., Lu, C.-Y., Zhuang, Y., Wang, C.-L., Yu, Y.-H., Wang, H.-Y., Lin, C., & Chen, C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.027 · Cited by 38
Jung, T., Pham, T.-N. N., Umeyama, A., Shoji, N., Hashimoto, T., Lee, J., & Takei, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.06.030 · Cited by 33
Han, L., Yao, S., Cao, S., Mo, G., Li, J., Cao, Y., & Huang, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s212666 · Cited by 32
Chang, J., Hung, L.-M., Chyan, Y., Cheng, C., & Wu, R.-Y. (2008) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nen068 · Cited by 31
Ma, C., Wei, Y., Liu, Q., Xin, Y., Cao, G., Wang, X., & Yang, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109167 · Cited by 27
Astragalus Saponins and Liposome Constitute an Efficacious Adjuvant Formulation for Cancer Vaccines
Zhang, X., Li, Y., Luo, L., Liu, Y., Yang, L., Guo, C., Li, Z.-D., Xie, X., Song, H., Yang, L., et al. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2369 · Cited by 26
Influence of total glucosides of paeony on PD‐1/PD‐L1 expression in primary Sjögren's syndrome
Chen, Y., Wang, Y., Xu, L., et al. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13391 · Cited by 25
Self-citationInhibition of mast cell secretion by oxidation products of natural polyamines
Vliagoftis, H., Boucher, W. S., Mak, L. L., & Theoharides, T. C. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90183-j · Cited by 24
Ghosh, S., Sarkar, M., Ghosh, T., Guha, I., Bhuniya, A., Saha, A., Dasgupta, S., Barik, S., Bose, A., & Baral, R. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.01.007 · Cited by 16
Huang, C.-H., Chang, C., Lin, C.-M., Wang, S.-T., Wu, M.-T., Li, E. I. C., Chang, H., & Lin, C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0852-y · Cited by 15
Yang, P., Du, J.-L., Wang, G. N.-K., Chia, J., Hsu, W.-B., Pu, P.-C., Sun, A., Chiang, C., & Wang, W.-B. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416651492 · Cited by 8
Cited by
CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma
Lu, Y., Liu, Y., Zuo, X., Li, G., Wang, J., Liu, J., Wang, X., Wang, S., Zhang, W., Zhang, K., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.044 · Cited by 82
Metadata
- Authors
- Dong, S., Guo, X., Han, F., He, Z., & Wang, Y.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 12
- Issue
- 3
- Pages
- 1163-1185
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3195008613
- Cited by
- 278
- References
- 160
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.